Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

Author(s): Oleksandra Katrych, Tessa M. Simone, Shara Azad, Shaker A. Mousa.

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 8 , Issue 6 , 2009

Become EABM
Become Reviewer


Multiple sclerosis (MS) is a chronic, debilitating condition mediated by inflammation and neurodegeneration. The ultimate goal of treatment is to delay or halt the progression of irreversible disability. Disease-modifying drugs (DMDs), including beta interferon and glatiramer acetate during phase III trials, have been shown to reduce relapse rates in relapsing-remitting multiple sclerosis (RRMS) as detected by magnetic resonance imaging (MRI). However, the longterm effects of DMDs on MS progression are not very clear; therefore, the aim of this paper is to evaluate the evidence available of the long-term effects of DMDs on reducing the progression of multiple sclerosis. A number of open-label, prospective extensions that followed a cohort of patients enrolled in double-blind, placebo-controlled trials were examined. Methodological difficulties faced in designing a trial of extended duration were hard to overcome, however, and long-term, open-label extensions of interferon and glatiramer acetate failed to show significant beneficial effects in delaying disability progression, questioning the cost-effectiveness of these therapies in the long-term.

Keywords: Multiple sclerosis, demylinating, disease-modifying agents, glatiramer acetate, interferon, relapse

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [512 - 519]
Pages: 8
DOI: 10.2174/187152709789824598
Price: $58

Article Metrics

PDF: 15